The staining pattern of a monoclonal antibody directed to the monomorphic determinant of HLA-DR antigens was examined on sections of human mammary gland tissues at various stages of differentiation as well as on 50 benign and 72 malignant breast lesions. Normal resting breast epithelium lacked HLA-DR, whereas late-pregnant and lactating epithelia expressed high levels of HLA-DR antigens, followed by a decline in the post-weaning regression period. Most benign breast lesions revealed heterogeneous staining ranging from very few up to 20-25% positive epithelial Greater variability was observed among carcinomas, where a small group (approximately 7%) of cases showing 40-95% positive tumour cells was found, in addition to negative tumours and those with the minority of HLA-DR expressing carcinoma cells. The density of the leukocytic infiltrate was higher in carcinomas than in either normal breast tissue or benign lesions, the HLA-DR phenotype of the mononuclear infiltrating cells lacking any obvious correlation with the HLA-DR status of the epithelial component. Immunoblotting analyses of whole-tissue lysates separated by SDS-PAGE confirmed the immunohistochemical data and demonstrated the reactivity with only one protein band predicted for HLA-DR alpha-chain. The combination of immunohistochemistry and autoradiography on sections of human reduction mammoplasty organoids cultured in collagen gels and labelled with tritiated thymidine revealed a lack of HLA-DR expression on proliferating breast epithelial cells suggesting factors other than cell kinetics must be responsible for induction of HLA-DR antigens seen in pregnant and lactating breast epithelium and some tumours.

Department of Immunology Research Institute of Clinical and Experimental Oncology Brno Czechoslovakia

See more in PubMed

In Vitro. 1977 May;13(5):316-28 PubMed

Hum Immunol. 1986 Aug;16(4):390-400 PubMed

Clin Exp Immunol. 1980 Sep;41(3):478-86 PubMed

Eur J Immunol. 1980 Dec;10(12):958-63 PubMed

Immunol Lett. 1982 May;4(5):231-5 PubMed

Cancer Res. 1983 Feb;43(2):660-8 PubMed

J Immunol. 1983 Jul;131(1):508-13 PubMed

J Natl Cancer Inst. 1983 Sep;71(3):507-16 PubMed

Immunology. 1983 Dec;50(4):613-24 PubMed

Cell. 1984 Jan;36(1):1-13 PubMed

Br J Cancer. 1984 Feb;49(2):161-72 PubMed

Clin Exp Immunol. 1984 Apr;56(1):215-21 PubMed

Nature. 1984 Dec 13-19;312(5995):639-41 PubMed

J Clin Pathol. 1985 Jan;38(1):12-7 PubMed

Int J Cancer. 1985 Feb 15;35(2):199-205 PubMed

Scand J Immunol. 1985 May;21(5):389-96 PubMed

Cancer Res. 1985 Jul;45(7):2957-61 PubMed

Int J Cancer. 1985 Jun 15;35(6):753-62 PubMed

Int J Cancer. 1985 Sep 15;36(3):299-306 PubMed

Am J Pathol. 1985 Sep;120(3):334-43 PubMed

J Cell Sci. 1985 Apr;75:1-16 PubMed

Br J Cancer. 1985 Oct;52(4):551-63 PubMed

Anticancer Res. 1986 Jan-Feb;6(1):79-83 PubMed

Lab Invest. 1986 Aug;55(2):123-5 PubMed

Am J Clin Pathol. 1986 Aug;86(2):153-60 PubMed

In Vitro. 1980 May;16(5):415-25 PubMed

Secretory component in differentiating normal epithelium, benign lesions and malignancy in the human breast as monitored by monoclonal antibodies